AKEBIA THERAPEUTICS, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent
AKEBIA THERAPEUTICS, INC. (AKBA) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent of 0.00% for the 12-month period ending 2020-12-31, per its 10-K filed 2021-02-25.
Discontinued › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense · last filed 2021-02-25
- AKEBIA THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2020 was 0.00%.
- AKEBIA THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2019 was 0.00%, a 100.00% decline from fiscal 2018.
- AKEBIA THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2018 was 3.10%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month |
|---|---|
| 2020-12-31 | 0.00% 10-K · filed 2021-02-25 |
| 2019-12-31 | 0.00% 10-K · filed 2021-02-25 |
| 2018-12-31 | 3.10% 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |